Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.
Treating anxiety and depression has been found to reduce emergency room visits and rehospitalizations for patients with heart disease, according to results of a study published in the Journal of the American Heart Association.1,2
“For patients who had been hospitalized for coronary artery disease or heart failure and who had diagnoses of anxiety or depression, treatment with psychotherapy, pharmacotherapy, or a combination of the 2 was associated with as much as a 75% reduction in hospitalizations or emergency room visits. In some cases, there was a reduction in death,” Philip Binkley, MD, MPH, executive vice chair of the department of internal medicine and emeritus professor of internal medicine and public health at The Ohio State University in Columbus, Ohio, said in the press release.1
Investigators of the study wanted to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals who were admitted to the hospital with coronary artery disease (CAD) or heart failure (HF) and were diagnosed with anxiety or depression. Individuals included were aged 21 to 64 years and had a first hospital admission for 2 claims for ischemic heart disease or HF over a 3-year period as well as 2 or more claims for any anxiety disorder or depression, according to the study authors. Patients with schizophrenia or psychosis, bipolar disorder, dementia, autism spectrum disorder, or intellectual disability were excluded from the study.2
There were 1563 individuals included in the study with 23.2% on antidepressant medication and receiving psychotherapy, 14.8% receiving psychotherapy alone, 29.2% receiving antidepressants alone, and 33% with no mental health treatment, according to the study authors. The mean age was 50.1 years, with 68% women and 80.9% White.2
Approximately 92.2% had an anxiety diagnosis and 55.5% had depression. The most prevalent comorbidities were disability, substance use, pulmonary disease, and diabetes without complications, the study authors said. The most commonly prescribed antidepressants included tricyclic antidepressants, antipsychotic medications, benzodiazepine, mood stabilizers, buspirone, and hydroxyzine. Cardiovascular medications included β‐blockers, calcium channel blockers, and angiotensin-converting enzymes inhibitors.2
Investigators found that pharmacotherapy, psychotherapy, and the combination of the 2 were related to reductions in hazard ratio for all-cause mortality, cardiovascular mortality, emergency department visits, and hospital readmissions compared with those who were untreated, the results showed. Psychotherapy combined with medication had a hazard ratio ranging from 0.33 to 0.35 for all-cause mortality. For psychotherapy alone and pharmacotherapy alone, the reductions ranged from 0.52 to 6.1 and 0.70 to 0.72, respectively.2
Additionally, reductions in mortality for CAD were seen but were not statistically significant, according to the investigators. Combined treatment with psychotherapy had the greatest reduction for emergency department visits and hospital readmissions, ranging from 0.26 to 0.33 and 0.25 to 0.23, respectively.2
For emergency department visits, psychotherapy alone and pharmacotherapy alone resulted in reductions of 0.47 to 0.52 and 0.51 to 0.059, respectively. For hospital readmissions, the reduction rates were 0.51 to 0.54 and 0.45 to 0.53, respectively.2
“Heart disease and anxiety/depression interact such that each promotes the other,” Binkley said in the press release. “There appear to be psychologic mechanisms that link heart disease with anxiety and depression that are currently under investigation. Both heart disease and anxiety/depression are associated with activation of the sympathetic nervous system. This is part of the so-called involuntary nervous system that increases heart rate, blood pressure and can also contribute to anxiety and depression.”1
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Subscribe
